XOMA Q3: Revenue $7.2M, net loss $17.2M ($14M impairment); Twist 50% interest acquired

XOMA Royalty Corp

2024-Q3 EPS reported -$1.20 revenue$19,773,000

Total income/revenue of $7.2M in Q3 2024 vs $0.8M in Q3 2023; cash receipts $9.9M.
Net loss of $17.2M vs $5.5M loss, driven by $14M non-cash impairment on Agenus royalty purchase agreement.
Acquired 50% economic interest in Twist Bioscience's 60+ partnered early-stage programs for $15M.
Cash and cash equivalents of $146.8M at Sept 30, 2024, down from $159.6M at Dec 31, 2023.
Zevra's MIPLYFFA (arimoclomol) received FDA approval for Niemann-Pick disease type C, adding commercial royalty.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.